Skip to main content
. 2006 May 9;94(11):1592–1598. doi: 10.1038/sj.bjc.6603129

Table 5. Alterations of CK18-Asp396 during second-, third- and fourth-line docetaxel therapy.

  CK18-Asp396 increase (days 5–7)
CK18 increase (days 5–7)
 
  (U l−1) Percent increase (U l−1) Percent increase (na)
Second docetaxel 49 (0–115)b 31.7 93 (−21–236) 18.3 54/54
Third docetaxel 22 (0–54) 16.1 47 (−4–163) 15.0 154/155
Fourth docetaxel 34 (13–98) 29.3 72 (2–202) 30.8 14/15
a

(CK18-Asp396/CK18).

b

Median (25th–75th percentile) alterations from day 5 to day 7.

CK18=Cytokeratin 18.

HHS Vulnerability Disclosure